Blog
EZ – Retriever® IR – Antigen Retrieval System – Simplifying IHC
In the realm of immunohistochemistry (IHC), achieving accurate and reliable results is paramount for researchers and clinicians alike. Antigen retrieval, a critical step in the IHC process, plays a pivotal role in unmasking antigens and optimizing antibody-antigen interactions. BioGenex’s EZ – Retriever® IR System offers a cutting-edge solution, simplifying antigen retrieval protocols and enhancing the efficiency of this essential procedure.
MART-1: An IHC Marker Useful in Advanced Melanoma Diagnosis and Melanocytic Differentiation
Introduction: Malignant melanoma, poses a significant health concern globally as it has a high mortality. Although it’s the most serious form of skin cancer, it is curable if diagnosed ahead of time. So, an early and accurate diagnosis plays a crucial role in improving patient outcomes. BioGenex, a leading biotechnology company, offers an...
Unravelling the mysteries of lung inflammation using BioGenex’s Anti- Surfactant Protein D (SFTPD) antibody
Surfactant protein D (SFTPD) is an essential component of the lung’s innate immune defense system. It belongs to the collectin family of proteins and is primarily produced by alveolar type II cells in the lungs. SFTPD plays a crucial role in the recognition and clearance of pathogens, allergens, and other foreign particles in the respiratory system.
PRAME: A Promising IHC Antibody to Diagnose Melanoma in Clinical and Research Systems
Melanoma, a type of skin cancer, can be challenging to diagnose accurately. Recognizing melanoma symptoms, such as the appearance of new moles or changes in existing moles, is crucial for early detection. Fortunately, recent advancements in immunohistochemistry (IHC) have provided valuable markers for the diagnosis and management of melanoma. One such marker is the preferentially expressed antigen in melanoma (PRAME), an autosomal cancer-testis antigen (CTA) gene and a tumor-associated antigen. In this article, we will explore the significance of PRAME in diagnosing melanoma, its potential as a biomarker for prognosis and treatment, and its role in immunotherapy and melanoma medical procedures.
Benchtop fully automated All-in-One ten slide system for Fluorescence in situ hybridization (FISH), ISH, miRNA and IHC
We are pleased to bring you the BioGenex NanoVIP a fully automated bench-top integrated system with visualization kits for fluorescence in situ hybridization (FISH), in situ hybridization (ISH), miRNA ISH, and immunohistochemistry (IHC). The compact 10-slide design provides reliable automation with eXACT™ temperature control modules for each...
MicroRNA in situ hybridization for cancer diagnosis
Summary: MicroRNAs (miRNA) are approximately 19–24 nucleotides in length and base-pair to complementary sites within messenger RNA (mRNA). Aided by the “RISC” complex this binding functions to promote down-regulation of the mRNA’s protein product. MicroRNAs are an important biomarker of cancer as a result of their involvement in multiple...
miRNA-ISH for Cancer of Unknown Primary
Summary: World-wide approximately 5% of all cancers are determined to have an occult or unknown primary location, upon initial assessment, prior to completing a full pathology report. [Oien] Unfortunately in 20-50% of CUP cases the primary tumor is never found. These cancers of unknown primary (CUP) result from metastasis. Occult cancer is most...